ストックスクリーナーアプリを入手
0.3598
4.59%
0.0158
前日終値:
$0.344
開ける：
$0.32
24時間の取引高:
590.80K
Relative Volume:
0.95
時価総額：
$17.49M
収益：
$1.14M
当期純損益:
$-56.27M
株価収益率:
-0.2964
EPS:
-1.2139
ネットキャッシュフロー:
$-51.94M
1週間 パフォーマンス:
+1.93%
1か月 パフォーマンス:
-5.79%
6か月 パフォーマンス:
-42.92%
1年 パフォーマンス:
-66.06%
1日の値動き範囲:
$0.32
$0.3613
1週間の範囲:
$0.295
$0.37
52週間の値動き範囲:
$0.27
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
名前
Werewolf Therapeutics Inc
セクター
電話
617-952-0555
住所
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.3598 | 17.49M | 1.14M | -56.27M | -51.94M | -1.2139 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.30 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-04-03 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-24 | 開始されました | Wedbush | Outperform |
| 2023-06-06 | 再開されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-25 | 開始されました | Evercore ISI | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-25 | 開始されました | Jefferies | Buy |
| 2021-05-25 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Werewolf Therapeutics Inc (HOWL) 最新ニュース
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock - Investing.com
Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com - Investing.com Canada
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock By Investing.com - Investing.com Canada
Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares - Stock Titan
Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech - Ad-hoc-news.de
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com - Investing.com South Africa
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock By Investing.com - Investing.com South Africa
Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
Form 144 Werewolf Therapeutics For: 29 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock - Investing.com
Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares - Stock Titan
Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL) - TradingView
Form 13D/A WEREWOLF THERAPEUTICS For: 26 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales - Stock Titan
Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors - Ad-hoc-news.de
Werewolf Therapeutics Inc (HOWL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Werewolf Therapeutics Inc (HOWL) Institutional Confidence - TradingKey
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock By Investing.com - Investing.com Australia
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock - Investing.com UK
[SCHEDULE 13D/A] Werewolf Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 22 June By Investing.com - Investing.com South Africa
Form 4 Werewolf Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
RA Capital funds trim Werewolf Therapeutics (HOWL) stake with 416,911-share sale - Stock Titan
RA Capital Management Reduces Stake in Werewolf Therapeutics Inc - GuruFocus
Werewolf Therapeutics Inc (HOWL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Werewolf Therapeutics Inc (HOWL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Werewolf Therapeutics Inc (HOWL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Werewolf Therapeutics Inc (HOWL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Werewolf Therapeutics Inc (HOWL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Werewolf Therapeutics Inc (HOWL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ra Capital Management reduces Werewolf Therapeutics stake by $173,757 - Investing.com India
RA Capital trims Werewolf Therapeutics (HOWL) stake with 448,836-share sale - Stock Titan
RA Capital adjusts Werewolf Therapeutics (HOWL) stake to 10.6% ownership - Stock Titan
Werewolf Therapeutics Inc (HOWL) 財務データ
収益
当期純利益
現金流量
EPS
3.27%
0.61%
大文字化:
|
ボリューム (24 時間):